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Peri-operative management of the surgical patient with diabetes: a guideline 
summary 
Abstract 
Background: Diabetes significantly increases the risk of morbidity and mortality associated with surgery. 
These guidelines target anesthetists, providing guidelines for management of the diabetic patients in the 
pre-operative, peri-operative and post-operative periods. Methods: The following paper summarizes the 
Association of Anaesthetists of Great Britain and Ireland clinical guidelines on peri-operative 
management of the surgical patients with diabetes 2015. Results: It is recommended that where possible 
all diabetic patients achieve an HbA1c less than 69 mmol/mol (8.5%) prior to surgery. On the day of 
surgery, fasting periods should be limited to one meal and if this is not possible, a variable-rate 
intravenous insulin infusion should be started. Intra-operatively blood glucose should remain between 6 
and 10 mmol/L. Post-operatively, the key to resuming normal diabetic management is through returning 
to an normal diet as soon as possible. Conclusions: The aim of management of a diabetic patient during 
the operative period is to maintain normal blood glucose levels (6 - 10 mmol/L). This is achieved through 
careful pre-operative planning, appropriate management of blood glucose levels and fluid balance intra-
operatively and a smooth transition to resume the patients normal diabetic management. 
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Peri-Operative Management of the Surgical Patient With 
Diabetes: A Guideline Summary
Leigh White
Abstract
Background: Diabetes significantly increases the risk of morbidity 
and mortality associated with surgery. These guidelines target anes-
thetists, providing guidelines for management of the diabetic patients 
in the pre-operative, peri-operative and post-operative periods.
Methods: The following paper summarizes the Association of Anaes-
thetists of Great Britain and Ireland clinical guidelines on peri-opera-
tive management of the surgical patients with diabetes 2015.
Results: It is recommended that where possible all diabetic patients 
achieve an HbA1c less than 69 mmol/mol (8.5%) prior to surgery. 
On the day of surgery, fasting periods should be limited to one meal 
and if this is not possible, a variable-rate intravenous insulin infusion 
should be started. Intra-operatively blood glucose should remain be-
tween 6 and 10 mmol/L. Post-operatively, the key to resuming normal 
diabetic management is through returning to an normal diet as soon 
as possible.
Conclusions: The aim of management of a diabetic patient during 
the operative period is to maintain normal blood glucose levels (6 - 
10 mmol/L). This is achieved through careful pre-operative planning, 
appropriate management of blood glucose levels and fluid balance 
intra-operatively and a smooth transition to resume the patients nor-
mal diabetic management.
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Introduction
The following paper summarizes the Association of Anaesthe-
tists of Great Britain and Ireland clinical guidelines on peri-
operative management of the surgical patients with diabetes 
2015 [1]. Diabetes significantly increases the risk of morbidity 
and mortality associated with surgery. The poor outcomes as-
sociated with diabetes is related to hypoglycemia and hyper-
glycemia, complex polypharmacy, increased infection rates, 
microvascular and macrovascular co-morbidities and insulin 
prescribing errors [2-8]. These guidelines target anesthetists, 
providing guidelines for management of the diabetic patients 
in the pre-operative, peri-operative and post-operative periods.
Primary Care and Surgical Outpatient Clinic
It is recommended that all patients undergoing elective surgery 
should have an HbA1c less than 69 mmol/mol (8.5%). This 
should be addressed at the time of referral for elective surgery. 
When assessed in the surgical outpatient clinic, there should 
be a recorded HbA1c less than 69 mmol/mol within 3 months 
leading up to the surgery. If this has not been achieved, then 
the surgery should be delayed to allow for better control. If this 
is not achievable such as in the presence of chronic infection 
or steroid treatment, the surgery should proceed with all risks 
explained to the patient. The risks include a 50% increase in 
mortality and two to three times the risk of surgical site infec-
tions, respiratory infections, myocardial infarction and acute 
kidney injury [2]. In addition to glycemic control, it is impor-
tant for the outpatient surgical team to have access to informa-
tion regarding type of diabetes, duration, complications and 
current management.
Pre-Operative Assessment and Management
The pre-operative assessment should occur well in advance to 
1) optimize glycemic control and 2) ensure all investigations 
are performed to assess co-morbidities. This recommendation 
is backed by the National Institute for Health and Care Excel-
lence (NICE) guidance on peri-operative testing [9]. At this 
time, the patient should be educated on the impact of the pre-
operative, peri-operative and post-operative periods on glyce-
mic control.
It is recommended that the patient be for day surgery with 
minimal fasting time, whilst maintaining euglycemia (6 - 10 
mmol/L). Pre-operatively if the patient is expected to only 
miss one meal, this may be facilitated through alterations to 
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their current diabetes management. Patients should also be ad-
vised to carry a source of glucose during the fasting period 
and that they are likely to experience erratic glycemic control 
following the surgery.
During the fasting period, the aim is to avoid hyperglyce-
mia and hypoglycemia. There are specific recommendations 
for insulin and oral hypoglycemic agents in the context of a 
short (one meal missed) fasting period. Once daily long act-
ing insulins whether given the night before or on the day of 
surgery should be reduced by 20% and blood glucose levels 
(BGLs) should be checked on admission. If a variable rate in-
travenous insulin infusion (VRIII) is used, it should continue at 
80% of the patients usual insulin dose. In patients using a twice 
daily biphasic or short acting insulin, there should be no dose 
adjustment the day prior to surgery. On the morning of surgery, 
half the calculated total dose should be given as an interme-
diate acting insulin. In patients on short acting insulin given 
three to five times per day, there should be no change in dose 
the night before. On the morning of surgery, the basal insulin 
should remain unchanged with bolus insulin omitted. All oral 
hypoglycemic agents should be taken as normal the night prior 
to surgery. On the day of surgery, metformin, GLP-1 analogues 
and pioglitazone should be taken as normal, unless the surgery 
requires contrast media in the case of metformin. Medications 
that should be withheld on the day of surgery include sulpho-
nylureas, meglitinides and acarbose. The only medication re-
quiring dose changes is SGLT-2 inhibitors, which are reduced 
by 50%. If a VRIII is being used all medications should be 
withheld, with the exception of GLP-1 inhibitors which can be 
taken as normal. It is recommended that VRIII should be used 
in patients who miss more than one meal, those with type-1 
diabetes, those with poorly controlled diabetes (HbA1c > 69 
mmol/mol) and those that require emergency surgery.
Intra-Operative Care and Monitoring
It is recommended that BGLs should be measured before 
and regularly during a surgery aiming for a target range of 
6 - 10 mmol/L. Diabetic ketoacidosis should be treated for if 
BGLs exceed 12 mmol/L and blood ketones are greater than 3 
mmol/L (or urine ketones > 2+ on dipstick). If hyperglycemia 
and not DKA is present intra-operatively, the patient should 
be managed with subcutaneous rapid acting insulin (no more 
than 6 IU). The BGL should be checked hourly and only given 
a second dose of insulin after 2 h. Initiation of a VRIII should 
only be considered in a type-2 diabetic who remains hypergly-
cemic. It is recommended that hypoglycemia of 4 - 6 mmol/L 
be treated with 50 mL of 20% glucose and if the BGL is < 4 
mmol/L, then 100 mL of 20% glucose should be given.
Fluid Management
In patients without a VRIII, Hartmann’s solution is the fluid of 
choice to avoid hyperglycemia and hyperchloremic metabolic 
acidosis. In patients with VRIII, it is recommended that glu-
cose 5% in saline 0.45% or potassium 0.3% be the initial fluid 
of choice. The rate of infusion should be 25 - 50 mL/kg/day to 
meet normal maintenance requirement. If non-hypervolemic 
hyponatremia occurs, the fluid of choice is either glucose 5% 
in 0.9% saline with 0.15% potassium or glucose 5% in 0.9% 
saline with 0.3% potassium. The addition of a balanced iso-
tonic solution may be used for optimal fluid balance.
Resuming “Normal” Medication and Diet Post-
Operation
It is recommended that patients with a new or changed intra-
operative insulin regiment be consulted on by a specialist dia-
betes team. Once a normal diet is resumed, oral hypoglycemic 
agents may be restarted. The exception is metformin, which 
should be withheld until estimated glomerular filtration rate 
exceeds 50 mL/min/1.73 m2. A VRIII in a type-1 patient needs 
to continue until 30 - 60 min after the first dose of subcutane-
ous insulin. Recommencement of subcutaneous insulin may 
require dose adjustment for food intake, post-operative stress 
or infection. The restarting of subcutaneous insulin must be 
prior to a meal.
Other Anesthetic Considerations
It is recommended that the use of dexamethasone be carefully 
considered due to the risk of hyperglycemia. If used, BGLs 
should be measured hourly for 4 h after administration. The 
use of regional anesthesia should also be carefully considered, 
as diabetic patients are at higher risk of developing epidural 
abscesses, hemodynamic instability (if autonomic neuropathy 
is present) and post-nerve block neuropathy.
Diabetes and Emergency Surgery
It is recommended that a VRIII should be used in the setting of 
an emergency surgery, unless there is concurrent DKA, which 
would require a fixed rate intravenous insulin infusion. The 
target BGL range of 6 - 10 mmol/L remains the same. Emer-
gency surgery in the context of DKA should be carefully con-
sidered and the decision making process should include the 
anesthetists, surgeons, intensivists and diabetologists. Intra-
operatively a fixed rate insulin infusion should be used, and 
this requires regular blood glucose monitoring and the admin-
istration of 20% glucose if BGLs fall below 14 mmol/L. In 
addition to the insulin infusion, where possible, long acting 
insulins should also be continued at 80% normal dose. The 
resuscitation fluid of choice is either Hartmann’s solution or 
normal saline with pre-mixed potassium chloride.
Safety
Insulin is one of the top five high risk medications due to the 
number of preparations, errors in prescribing and administra-
tion. Specifically, VRIIIs are associated with hyperglycemia, 
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hypoglycemia, hyponatremia and ketosis on cessation. It is ad-
vised that patients on VRIIIs have hourly BGLs and that ces-
sation in type-1 diabetics does not occur without overlapping 
subcutaneous insulin therapy.
It is recommended that metformin only be withheld pre-
operatively and peri-operatively if the patient has or is at risk 
of acute kidney injury. Due to the risk of lactic acidosis met-
formin should only be resumed once estimated glomerular fil-
tration rate exceeds 50 mL/min/1.73 m2.
Conclusions
The aim of management of a diabetic patient during the op-
erative period is to maintain normal blood glucose levels (6 
- 10 mmol/L). This is achieved through careful pre-operative 
planning, appropriate management of blood glucose levels and 
fluid balance intra-operatively and a smooth transition to re-
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